Developing RNAi Therapeutics (Part I)
An interview with Patrick Lu, Founder and CEO of Sirnaomics, Inc.
418 views
00:09:00 - Uploaded by Essinova on September 14, 2009
Essinova host BeiBei Song interviewed Patrick Lu, Ph.D., Founder and CEO of Sirnaomics, Inc, about the science and business of developing RNAi therapeutics during the IBC Oligonucleotide Therapeutics conference in Boston.
In this segment, Dr. Lu comments on the potential of RNAi therapeutics as the "Next Big Thing" in drug discovery and development, the scientific challenges of realizing such potential, and the latest technological development in the field as evidenced in the meeting.
Tags: RNAi, siRNA, miRNA, oligonucleotides, Sirnaomics, Patrick Lu, IBC, DDD
RELATED
COMMENTS
There are 0 comments. You must be logged in to comment.
Therapeutics & Vaccines
-
Vitae's Computationally-grown Molecules and Four Tough Diseases
-
Expanding Access to Patients in Need Around the World
-
Five Prime Therapeutics - Protein Medicines
-
Chemokine Therapeutics from ChemoCentryx
-
Developing RNAi Therapeutics (Part I)
-
Developing RNAi Therapeutics (Part II)
-
Developing RNAi Therapeutics (Part III)
